Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Arrowhead Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€19.62
30.11.23
-
30.11.24
12.62%
08.12.23

Could be very worthwhile Investment >20% year
buy
Gerresheimer AG

Start price
Target price
Perf. (%)
€72.50
02.12.22
-
02.12.23
22.69%
03.12.23

buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€3.58
21.11.22
-
21.11.23
-85.09%
22.11.23

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Innovative
Future proof or reliable business model
Sartorius AG VZO

Start price
Target price
Perf. (%)
€396.90
15.11.22
-
15.11.23
-30.86%
16.11.23

Sartorius AG VZO

Start price
Target price
Perf. (%)
€396.90
15.11.22
-
15.11.23
-30.86%
16.11.23

buy
Evotec SE

Start price
Target price
Perf. (%)
€19.00
12.11.22
€25.00
12.11.23
-7.37%
12.11.23

Could be worthwhile Investment >10% per year
Standard Investments for future growth
Innovative
Some uniques
PTC Therapeutics Inc.

Start price
Target price
Perf. (%)
€17.20
28.10.23
€8.00
28.10.24
-4.07%
11.11.23

Probably not worthwhile Investment
Revenue decline/stagnation expected
Lower EBIT Margin than peer group
negative Cash Flow expected
Medpace Holdings Inc

Start price
Target price
Perf. (%)
€218.90
25.10.22
€190.00
25.10.23
11.47%
26.10.23

Could be worthwhile Investment >10% per year
buy
Mirati Therapeutics Inc.

Start price
Target price
Perf. (%)
€59.10
05.10.23
-
05.10.24
-8.93%
15.10.23

Could be worthwhile Investment >10% per year
Acadia Pharmaceuticals

Start price
Target price
Perf. (%)
€19.60
30.09.23
€9.00
30.09.24
11.22%
14.10.23

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
PTC Therapeutics Inc.

Start price
Target price
Perf. (%)
€24.00
16.09.23
€12.00
16.09.24
-13.33%
30.09.23

Probably not worthwhile Investment
Revenue decline/stagnation expected
Lower EBIT Margin than peer group
negative Cash Flow expected
Canopy Growth Corp

Start price
Target price
Perf. (%)
€1.30
14.09.23
-
14.09.24
-1.50%
16.09.23

Probably not worthwhile Investment
buy
PTC Therapeutics Inc.

Start price
Target price
Perf. (%)
€25.20
15.09.23
-
15.09.24
-4.76%
16.09.23

Could be very worthwhile Investment >20% year
buy
Orpea Nom.

Start price
Target price
Perf. (%)
€1.32
08.09.23
-
08.09.24
10.08%
15.09.23

Could be very worthwhile Investment >20% year
buy
Nektar Therapeutics

Start price
Target price
Perf. (%)
€0.95
07.08.23
-
07.08.24
-29.26%
19.08.23

Could be worthwhile Investment >10% per year
Good culture
Capable Management
Few uniques
Sage Therapeutics Inc.

Start price
Target price
Perf. (%)
€15.10
07.08.23
-
07.08.24
21.19%
18.08.23

Capable Management
Risky Investment
No uniques
buy
PTC Therapeutics Inc.

Start price
Target price
Perf. (%)
€51.50
16.08.22
-
16.08.23
-27.77%
16.08.23

buy
Neurocrine Bioscience

Start price
Target price
Perf. (%)
€104.86
16.08.22
-
16.08.23
-6.73%
16.08.23

buy
QIAGEN NV

Start price
Target price
Perf. (%)
€48.30
12.08.22
€55.00
12.08.23
-17.99%
13.08.23

buy
QIAGEN NV

Start price
Target price
Perf. (%)
€48.30
12.08.22
€55.00
12.08.23
-17.99%
13.08.23

buy
Global Blood Therapeutics Inc

Start price
Target price
Perf. (%)
€64.36
10.08.22
-
10.08.23
6.49%
10.08.23

buy
Amicus Therapeutics Inc.

Start price
Target price
Perf. (%)
€12.10
10.08.22
-
10.08.23
3.34%
10.08.23

buy
MorphoSys AG

Start price
Target price
Perf. (%)
€22.29
09.08.22
€28.00
09.08.23
24.14%
10.08.23

buy
MorphoSys AG

Start price
Target price
Perf. (%)
€22.29
09.08.22
€28.00
09.08.23
24.14%
10.08.23

buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€210.00
04.08.22
-
04.08.23
-17.71%
04.08.23